Claudio Botti

4.7k total citations
143 papers, 3.6k citations indexed

About

Claudio Botti is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Claudio Botti has authored 143 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 48 papers in Cancer Research and 42 papers in Molecular Biology. Recurrent topics in Claudio Botti's work include Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (16 papers). Claudio Botti is often cited by papers focused on Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (16 papers). Claudio Botti collaborates with scholars based in Italy, United States and Malaysia. Claudio Botti's co-authors include Paolo Visca, Marcella Mottolese, Piero Alò, Ugo Di Tondo, Pier Giorgio Natali, Antonella Mangoni, Patrizia Vici, Diana Giannarelli, Valeria Sebastiani and Franco Di Filippo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Claudio Botti

134 papers receiving 3.5k citations

Peers

Countries citing papers authored by Claudio Botti

Since Specialization

Citations

This map shows the geographic impact of Claudio Botti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Botti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Botti more than expected).

Fields of papers citing papers by Claudio Botti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio Botti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Botti. The network helps show where Claudio Botti may publish in the future.

Co-authorship network of co-authors of Claudio Botti

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio Botti. A scholar is included among the top collaborators of Claudio Botti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio Botti. Claudio Botti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preoperative Magnetic Seed Versus Wire‐Guided Localization in the Treatment of Nonpalpable Breast Cancer: A Retrospective Observational Study at a Tertiary Care Center 2025 ·International Journal of Breast Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Antonello Vidiri, Claudio Botti	0
2	Breast and cervical cancer in transgender men: literature review and a case report 2024 ·Therapeutic Advances in Medical Oncology ·(unknown), (unknown), (unknown), (unknown), Benito Chiofalo, Giuseppe Sanguineti, Laura Pizzuti, Eriseld Krasniqi, Maddalena Barba, Domenico Sergi, Francesco Lombardo, Francesco Romanelli, Claudio Botti, Giovanni Zoccali, Gennaro Ciliberto, Patrizia Vici	2
3	Reverse strategy to locally advanced breast implant-associated anaplastic large cell lymphoma: A case report 2023 ·Frontiers in Oncology ·(unknown), Francesco Marchesi, Marco Clementi, Letizia Perracchio, Francesca Palombi, (unknown), Claudio Botti, (unknown)	0
4	Regina Elena Institute (R.E.I.) Protocol for Breast Implant Salvage: Preliminary Results 2023 ·Clinical Breast Cancer ·Giovanni Zoccali, (unknown), (unknown), (unknown), Claudio Botti, Roy De Vita	1
5	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial 2020 ·Cancers ·Laura Pizzuti, Eriseld Krasniqi, Chiara Mandoj, Daniele Marinelli, Domenico Sergi, (unknown), G Paoletti, Claudio Botti, (unknown), Francesca Ferranti, Isabella Sperduti, Letizia Perracchio, Giuseppe Sanguineti, Paolo Marchetti, Gennaro Ciliberto, Giacomo Barchiesi, Marco Mazzotta, Maddalena Barba, Laura Conti, Patrizia Vici	2
6	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation 2020 ·Cell Death and Differentiation ·Valeria Canu, Sara Donzelli, Andrea Sacconi, Federica Lo Sardo, Claudio Pulito, Noa Bossel Ben‐Moshe, Anna Di Benedetto, Paola Muti, Claudio Botti, Eytan Domany, Silvio Bicciato, Sabrina Strano, Yosef Yarden, Giovanni Blandino	25
7	Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 2017 ·BMC Cancer ·Maddalena Barba, Patrizia Vici, Laura Pizzuti, Luigi Di Lauro, Domenico Sergi, Anna Di Benedetto, Cristiana Ercolani, Francesca Sperati, Irene Terrenato, Claudio Botti, Lucia Mentuccia, Laura Iezzi, Teresa Gamucci, Clara Natoli, Ilio Vitale, Marcella Mottolese, Ruggero De Maria, Marcello Maugeri‐Saccà	7
8	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients 2014 ·Journal of Cancer ·Patrizia Vici, Laura Pizzuti, Teresa Gamucci, Domenico Sergi, Francesca Conti, G. Zampa, Pietro Del Medico, Roy De Vita, (unknown), Claudio Botti, (unknown), Federica Tomao, Isabella Sperduti, Luigi Di Lauro	6
9	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study 2011 ·Journal of Experimental & Clinical Cancer Research ·Patrizia Vici, Giuseppe Colucci, Francesco Giotta, Domenico Sergi, Gianfranco Filippelli, Pasquale Perri, Claudio Botti, Enrico Vizza, (unknown), Laura Pizzuti, Agnese Latorre, Diana Giannarelli, Massimo Lopez, Luigi Di Lauro	18
10	Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. 2010 ·PubMed ·(unknown), (unknown), Claudio Botti, (unknown), (unknown), (unknown)	20
11	A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines 2008 ·Oncology ·Patrizia Vici, Luigi Di Lauro, Domenico Sergi, Paolo Foggi, (unknown), Marcella Mottolese, Francesco Giotta, (unknown), Serena Corsetti, Diana Giannarelli, Claudio Botti, Massimo Lopez	11
12	The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors 2006 ·Clinical Cancer Research ·Francesca Di Modugno, Marcella Mottolese, Anna Di Benedetto, Andrea Conidi, Flavia Novelli, Letizia Perracchio, Irene Venturo, Claudio Botti, Elke Jäger, Angela Santoni, Pier Giorgio Natali, Paola Nisticò	74
13	Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer 2004 ·Journal of Cellular Physiology ·Marcella Mottolese, (unknown), Claudio Botti, Anna Maria Cianciulli, Roberta Merola, Simonetta Buglioni, Maria Benevolo, Diana Giannarelli, Ferdinando Marandino, R. Perrone Donnorso, Irene Venturo, Pier Giorgio Natali	15
14	Role and prognostic significance of CD44s expression in colorectal cancer. 2003 ·PubMed ·Paolo Visca, Franca Del Nonno, Claudio Botti, Ferdinando Marandino, Valeria Sebastiani, Ugo Di Tondo, R. Perrone Donnorso, Giorgio Trombetta, (unknown), (unknown)	15
15	Cervical dysplasia, ploidy, and human papillomavirus status correlate with loss of Fhit expression. 2001 ·PubMed ·Andrea Vecchione, Nicola Zanesi, Giorgio Trombetta, Deborah French, Paolo Visca, (unknown), Claudio Botti, Carlo M. Croce, Rita Mancini	17
16	Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy 2000 ·Journal of Cancer Research and Clinical Oncology ·Marcella Mottolese, Maria Benevolo, Girolamo Del Monte, Simonetta Buglioni, Paola Papaldo, Cecilia Nisticò, Franco Di Filippo, Stefania Vasselli, Patrizia Vici, Claudio Botti	17
17	99Tcm-MIBI scintimammography in 300 consecutive patients 1999 ·Nuclear Medicine Communications ·A. Tofani, Rosa Sciuto, (unknown), Anna Festa, Rosella Pasqualoni, Salvatore Giunta, Marcella Mottolese, Maria Benevolo, Claudio Botti, C.L. Maini	26
18	Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients 1999 ·International Journal of Cancer ·(unknown), Marcella Mottolese, Simona Cascioli, Maria Benevolo, (unknown), Francesca Di Modugno, (unknown), Francesco Gentile, Claudio Botti, Irene Venturo, Pier Giorgio Natali	9
19	Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients 1997 ·JNCI Journal of the National Cancer Institute ·Paola Nisticò, Caterina Mammi, (unknown), Pier Giorgio Natali, Marcella Mottolese, Maria Benevolo, Irene Venturo, Claudio Botti, Francesco Gentile, (unknown)	14
20	Parkinson's Disease Affects Automatic and Spares Intentional Verbal Learning a Stochastic Approach to Explicit Learning Processes 1995 ·Cortex ·P. Faglioni, M. Scarpa, Claudio Botti, Vera Ferrari	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact